Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer (NCT05722327)

🧪 Interventions in This Study

• MRTX849 (DRUG)
• Irinotecan (DRUG)
• Cetuximab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Colon Cancer

• CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab — Fairway, Kansas
• A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors — Basking Ridge, New Jersey
• Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality — Rochester, Minnesota
• The Exercise And Colorectal Cancer Treatment Trial — Baton Rouge, Louisiana
• Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer — Atlanta, Georgia
• The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer — Gilbert, Arizona

Explore by condition: All Colon Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.